Orthocell Ltd has released a press release.
OCC Secures Rights to High-Value Bone Regeneration Tech
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Orthocell
- $30m Placement Sees Orthocell Positioned for Rapid Growth
- Trading Halt
- Another Record Revenue Quarter for Orthocell
- First Distributor signed for Remplir in $75m Canadian Market
- Globally Significant Opportunity Emerges as Remplir™ is used in Nerve-Sparing Prostate Cancer Surgery
Later from Orthocell
- HK Distributor Signed as Remplir Expands in the Asian Market
- Remplir Launches in Hong Kong with First Surgical Case
- 2nd Distributor in Canada, Entire $75m Market Now Covered
- Remplir gains momentum in nerve-sparing prostate surgery
- Remplir™ Nerve Sparing Prostate Cancer Surgery Commercial Opportunity Gathers Momentum with ~100 Surgeries Now Performed with Multiple Surgeons Nationwide
Follow Orthocell into a list and get an email when it puts out news.
Follow Orthocell